1. Introduction {#sec1}
===============

Bisphosphonates (BP) are antiresorptive drugs used in the management of conditions as diverse as osteoporosis and metastatic bone diseases. These drugs are widely administered and generally well tolerated by patients. In 2003, Marx et al. \[[@B1]\] first reported a nonhealing necrosis of the maxillofacial region in some patients taking BPs.

In the last decade researchers have discovered that BPs not exclusively cause osteonecrosis of jaws, as other drugs, such as antiresorptive (bone-targeted) agents like denosumab, but also were found to cause it. In addition, monoclonal antibodies able to bind and selectively inhibit VEGF-A, specifically mTOR inhibitors, can also cause osteonecrosis of the jaw \[[@B2]--[@B6]\].

For this reason, in 2014 the bisphosphonate-related osteonecrosis of the jaw (BRONJ) nomenclature was changed by the position paper of the American Association of Oral and Maxillofacial Surgeons (AAOMS) special committee on Medication-Related Osteonecrosis of the Jaws (MRONJ) \[[@B7]\]. The term "medication-related osteonecrosis of the jaws" (MRONJ) refers to a complication associated with groups of medications, such as antiangiogenic or antiresorptive drugs \[[@B8]\]. These medications can have different indications depending on their mode of administration (Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}) \[[@B9], [@B10]\].

According to AAOMS, MRONJ is defined as an exposition of necrotic bone in the oral cavity lasting more than 8 weeks, in patients who took antiresorptive or antiangiogenic drugs; these patients have not been exposed to head and neck radiotherapy, nor show signs of bone metastases in the maxillofacial region \[[@B7]\].

A number of systemic risk factors have been associated with increased likelihood of MRONJ; they are summarised in [Table 3](#tab3){ref-type="table"} \[[@B11], [@B12]\].

Dental extraction or other surgical procedures such as apicectomies or cystectomies have been found in between 52% and 80% of MRONJ patients\' medical history \[[@B13]--[@B15]\].

During the last decade AAOMS has revised and proposed a clinical staging classification system of the disease in an attempt to guide clinicians and surgeons to an appropriate therapeutic approach ([Table 4](#tab4){ref-type="table"}).

The management of MRONJ is reported to be very challenging and with no current "gold standard". Published studies have reported a number of approaches to treatment, with widely varying success rates, ranging from no or limited to radical surgery. The ideal outcome is total eradication of MRONJ along with an improvement of patients\' quality of life through pain release and infection management \[[@B16]\].

Conservative treatment was considered to be partially successful, with resolution reported in only 50% of cases; particular concerns have been reported on MRONJ at clinical stages II and III \[[@B17]--[@B19]\]. In case conservative treatments fail, surgical approaches like local debridement, osteoplasty, and segmental osteotomy are normally performed \[[@B20], [@B21]\].

However, patients that show evidence of MRONJ stage III with severe pain, infection, pathologic fracture, extra-oral fistula, or osteolysis extending to the inferior border of the mandible require an invasive type of surgery which might result in a disabling outcome \[[@B7], [@B16], [@B22]\].

The absence of a well-established surgical treatment protocol in scientific literature makes it difficult to conduct therapy in advanced cases of the disease.

Up to date, there is no standard treatment for MRONJ associated with antiresorptive and antiangiogenic therapies. Several treatment options have been described since MRONJ was first reported. Although the initial stages of MRONJ seem to respond quite well to conservative treatments or limited bone debridement if conservative treatment fails, the treatment for stage III lesions remains still controversial \[[@B23], [@B24]\].

The objective of this review is to evaluate the outcome of free vascularised osseous tissue transfer and/or osteofasciocutaneous free flap as treatment for patients affected by MRONJ stage III. Systematic reviews have been already published. However, these reviews were not performed in a standardised manner or did not follow strict criteria. Moreover the previous reviews did not consider antiangiogenic drugs in the search criteria. This has resulted in lack of quality assurance, summarised in [Table 5](#tab5){ref-type="table"} \[[@B49]--[@B53]\]. This review aims to improve the quality of previous research and expand on the current data available.

2. Materials and Methods {#sec2}
========================

This systematic review was performed according to PRISMA guidelines \[[@B25]\].

The following the databases were used for the review: PubMed/MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL). A three-stage screening approach was used to ensure precision and the quality of the search. The screening of titles and abstracts was carried out independently by three authors (AH, UH, and RS) to eliminate any irrelevant materials (i.e., reviews, animal studies, nonclinical studies, and studies that did not report on patients undergoing to free tissue graft). Disagreements were resolved by discussion.

A data screening and abstraction form was used to

\(1\) verify the study eligibility derived from the above inclusion/exclusion criteria,

\(2\) carry out the methodological quality assessment,

\(3\) extract data on study characteristics and outcomes for the included studies.

The authors of any studies eligible for inclusion in the review, yet without sufficient information, were contacted directly ([Figure 1](#fig1){ref-type="fig"}).

2.1. Criteria for Inclusion in This Review {#sec2.1}
------------------------------------------

### 2.1.1. Types of Studies {#sec2.1.1}

The types of studies included in the research strategy were published or unpublished randomised control trials, case-controlled trials, case series, retrospective studies, and case reports. Papers were obtained from January 2003 to June 2017. Animal studies and those including patients with previous history of radiation therapy to the head and neck regions were excluded. No language restrictions were imposed to the search.

### 2.1.2. Types of Participants {#sec2.1.2}

The review considered studies involving patients who developed MRONJ and subsequently underwent free vascularised osseous tissue transfer and/or osteofasciocutaneous free flap reconstruction. No restriction of age, gender, or ethnic origin was applied. There was no restriction on the minimum number of patients included in the studies.

### 2.1.3. Types of Interventions {#sec2.1.3}

Only free vascularised osseous tissue transfer and/or osteofasciocutaneous free flap reconstruction were considered.

### 2.1.4. Types of Outcome Measures {#sec2.1.4}

*Primary Outcomes*. Primary outcome measures of the review included the success rate of free flap without any restrictions in follow-up. The other considered measures were the frequency of MRONJ recurrence in the free flap or in the surgical residual jaw bone.

*Secondary Outcomes*. The secondary measures of the review entailed perioperative complications and those at follow-up, including the most common cause of the MRONJ and the time during which the patient was treated with the antiresorptive or antiangiogenic drugs prior ONJ.

2.2. Data Extracted {#sec2.2}
-------------------

Data extracted from the eighteen studies included number of patients, patient sex, and age, predisposing factors for, and localisation of, MRONJ, type of antiangiogenic or antiresorptive drugs and their cumulative dose, clinical indications for the drug or combined therapy, extent of the surgical excision, type of free vascularised tissue reconstruction, free flap failure, immediate complications, follow-up time, and MRONJ recurrence.

All selected papers were carefully read to identify author(s), year of publication, study design, population and treatment characteristics, and number of patients with recurrent MRONJ.

In case of missing information, we contacted the authors and gave them 6 weeks to reply. If the information was still missing we then indicated the missing data as "Not Reported (NR)" in the text and in the tables.

3. Results {#sec3}
==========

Results were expressed in descriptive statistics. No randomised controlled clinical trials or case-controlled studies comparing free flap reconstruction after resection in MRONJ patients were found. A total number of 18 articles we included in the study. All the published dates were described in case report (no. 6) and case series (no. 12) from 2008 to 2017 ([Table 6](#tab6){ref-type="table"}). A total of 83 patients, 47 females (56.62%), 19 males (22.89%), and missing information for 20.49% (NR) of the cases, were treated using vascularised osseous tissue transfer and/or osteofasciocutaneous free flap reconstruction.

The most common indications for antiresorptive or antiangiogenic treatment were breast cancer (28.91%), multiple myeloma (22.89%), osteoporosis (14.45%), prostate cancer (9.63%), lung cancer (2.40%), myeloid-leukemia and osteoporosis (1.20%), pain syndrome (1.20%), and NR in the 19.32% of the cases ([Table 7](#tab7){ref-type="table"}). The most common site for MRONJ was the mandible 97.59% and 2.41% in the maxilla ([Table 8](#tab8){ref-type="table"}).

Zoledronate was responsible for the majority of the MRONJ with 42.16 %, then pamidronate 7.22%, alendronate 8.43%, ibandronate 2.40%, and etidronate 1.20%. A combination of the following drugs and the relative incidence percentage were also found responsible:

zoledronate and pamidronate (13.25%);

zoledronate and clodronate (1.20%);

zoledronate and denosumab (1.20%);

pamidronate and denosumab (1.20%);

alendronate, risedronate, and pamidronate (1.20%).

A total of 20.54% patients presented missing information with regard to the type of drug used.

69.90% of the cases missed information on the causes of the MRONJ.

The most commonly utilised vascularised free flap reconstruction was fibula free flap (81.92%), followed by iliac crest (12.04%) and scapula (6.02%).

The most frequent type of resection was subtotal (32.53%), followed by segmental (26.50%) and partial (2.40%). However a large percentage of missing data was found regarding the type of resection (NR 38.57%) ([Table 9](#tab9){ref-type="table"}).

The patients were followed for a period of time ranging from 2 weeks up to 99 months.

Radiographic imaging with CT, cone-beam, and/or orthopantomogram was obtained during follow-up in 95% of the cases.

At follow-up and after free flap reconstruction, recurrence of MRONJ (6.02%) was observed in 5 patients: two of the patients (2.40%) on the contralateral unresected part of the jaw, other two patients (2.40%) on the margin of the resection, and one patient (1.20%) on the grafted flap. The overall free flap failure rate registered was 3.61% ([Table 10](#tab10){ref-type="table"}).

3.1. Review Quality Assessment Data {#sec3.1}
-----------------------------------

All the studies and data extraction included in the systematic review were qualitative and the risk of bias assessed independently by the authors. The authors used the CARE Checklist for case report and the Modified Delphi Checklist for the case series studies.

In the six case report studies, we identified lack of clarity in many of the thirteen domains, with missing information. We found that the lack of clarity was predominantly on follow-up and diagnostic procedure at the time of follow-up. Hence we concluded the level of bias to be high for all the included case report studies.

In the twelve case series studies, we reported a consistent lack of clarity in some of the seven domains, predominantly regarding the outcome measurement methods. Moreover, we identified some missing information in few other domains; hence we considered the level of bias to be high for all studies

We contacted the authors of these clinical cases to clarify this bias; however we were unable to recover the missing information.

4. Discussion {#sec4}
=============

Some antiresorptive drugs such as BP or denosumab have demonstrated to improve the quality of life in patients affected by bone metastasis, osteoporosis, osteopenia, and Paget disease. Additionally, a new antiangiogenic therapy has been successfully used for specific cancer treatments. However, this has remarkably increased the risk of developing MRONJ. This risk is greater in patients who require a higher administration dosage and an intake period greater than 2 years \[[@B14], [@B26], [@B27]\].

Moreover, literature has reported that demography, corticosteroid therapy, systemic factors, and genetic factors have been associated with MRONJ. A recent review report showed a wide-ranging MRONJ incidence from 0 to 27.5% in individuals exposed to intravenous BPs, with a mean incidence of 7%, whereas it ranges from 0.1% to 0.06% in oral administrations \[[@B28]--[@B30]\].

Etiopathogenesis of MRONJ is not yet fully understood.

Although no gold standard is currently available for the treatment of jaw osteonecrosis, a number of studies debate which MRONJ stage benefits the most from surgical therapy \[[@B24], [@B32]\]. In general, for early stages of the disease (MRONJ 0 and I) conservative treatments might be sufficient; surgical treatment should be restricted to advanced stages (MRONJ II and III) or after failure of conservative treatments \[[@B7], [@B32]\].

The majority of researches as well as AAOMS consider conservative treatments as the treatment of choice of MRONJ.

However, there is not a robust evidence from clinical trials as treatment recommendations mostly come from expert opinions and are, therefore, characterised by a low level of evidence \[[@B24], [@B28]\].

The authors of the 2009 AAOMS position statement recommend reserving resection and immediate reconstruction to patients with stage III of the disease; however, positive outcomes have been noted in patients with stages II and III. Having said that no recommendations were given on which type of reconstruction was to be considered the most predictable \[[@B28]\]. The benefits of surgical management of MRONJ have been extensively debated in literature and radical surgery seems to offer more predictable and curative results. However, surgical treatment of early stages of MRONJ remains controversial \[[@B28], [@B32]--[@B34]\].

Aggressive radical surgery is offered only to symptomatic patients with extensive osteonecrosis, including those who have previously failed conservative treatments \[[@B35]\].

This review has indicated that surgical therapy may represent a treatment option for patients affected by MRONJ stage III resulting in high success rates. Mucke et al. and Caldroney et al. have documented excellent outcomes in treating patient affected by MRONJ stage III in large cohort studies \[[@B36], [@B37]\]. Since 2008 microvascular reconstruction of the jaw has been documented as a viable option for MRONJ. This systematic review confirmed that microsurgical reconstruction therapy represents a feasible alternative in case of treatment escalation.

Even though the majority of papers included in this study were case reports and small case studies, the outcome of free flap treatment has been promising with a significant low recurrence of MRONJ and minimal surgical complications \[[@B49], [@B50], [@B38]--[@B37]\].

The MRONJ recurrence rate found by this systematic review was 6.02% (5 patients). The predominant recurrence sites were the contralateral unresected part of the jaw (2 cases) and the margin of the resection (2 cases), both bearing an overall recurrence rate of 2.40%. Just one case of recurrence was found on the vascular reconstruction.

Infection was the most frequent complication found with 6.02% incidence. The overall free flap success rate was 96.39%. Three free flaps failed during a follow-up period ranging from 2 weeks up to 99 months.

Amongst all the types of reconstruction, free flap fibula was the most chosen, followed by iliac crest and scapula with success rates, respectively, of 97.60%, 98.80%, and 100%.

Antiresorptive drugs were explicitly discontinued in only three studies out of the eighteen, while no mention was reported in the remaining studies \[[@B40], [@B42], [@B35]\]. It is unclear if the discontinuation strategy leads to a better surgical outcome due to the long skeletal life of some antiresorptive drugs.

In line with the growing body of literature, our findings confirm positive results in treating patients with MRONJ using free flaps microvascular reconstruction. In order to obtain a possible resolution of MRONJ, patients with reasonable life expectancy should be considered for microvascular flap reconstruction after aggressive resection of the diseased bone.

5. Conclusion {#sec5}
=============

MRONJ is a significant adverse effect amongst patients under antiresorptive agents. Although MRONJ pathogenesis remains unclear, significant progress has been made with respect to the diagnosis and staging of the disease, as well as with risk-reduction strategies and treatments. This systematic review based on multiple-reviewer quality assessment criteria was only able to select articles that meet Level 4 of the Oxford Evidence-based medicine scale. Due to the nature of the MRONJ incidence and the critical condition of the patients affected by the primary disease, it is difficult to improve the quality of evidence unless a common effort is applied. Therefore, the authors believe that additional quality studies, such as control multicentre studies or case-controlled studies, are necessary to support the hypothesis of this study.
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###### 

Antiresorptive drugs used in oncologic and nononcologic patients. Btl: bottle; IM: intramuscular; IV: intravenous; MM: multiple myeloma; PO: orally; SC: subcutaneous; SRE: skeletal-related event; Tab: tablet.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Pharmacologic active ingredient**             **Formulation**     **Route of administration**   **Indication and frequency**
  ----------------------------------------------- ------------------- ----------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Alendronic acid (sodium salt)                   Tab 70 mg\          PO                            Treatment of postmenopausal osteoporosis (70 mg/week)\
                                                  Tab 10 mg                                         Treatment of osteoporosis in men (70 mg/week)\
                                                                                                    Treatment and prevention of osteoporosis induced by glucocorticoids (70 mg/week)

                                                                                                    

  Alendronic acid + cholecalciferol               Tab 70 mg/5600 UI   PO                            Treatment of postmenopausal osteoporosis in patients with unsupplemented vitamin D deficit (70 mg/week)

                                                                                                    

  Ibandronic acid (monosodium salt monohydrate)   Tab 50 mg\          PO\                           Prevention of SREs in breast cancer patients with bone metastases (50 mg/day p.o. or 6 mg every 3--4 weeks iv.)\
                                                  Btl 6 mg/6 ml\      IV\                           Treatment of hypercalcemia of malignancy\
                                                  Tab 150 mg\         PO\                           Treatment of postmenopausal osteoporosis in patients at high risk of fracture (150 mg/4 weeks p.o. or 3 mg every 3 months iv.)
                                                  Btl 3 mg/3 ml       IV                            

                                                                                                    

  Neridronate acid\                               Btl 25 mg/2 ml\     IV/IM.\                       Osteogenesis imperfecta (2 mg/kg/3 months)\
  (sodium salt)                                   Btl 100 mg/8 ml     IV                            Paget\'s bone disease (different schedules)

                                                                                                    

  Pamidronic acid (disodium salt)                 Btl 15 mg/5 ml\     IV                            Prevention of SREs in breast cancer patients with bone metastases or MM with bone lesions (60--90 mg every 3--4 weeks)\
                                                  Btl 30 mg/10 ml\                                  Treatment of hypercalcemia of malignancy
                                                  Btl 60 mg/10 ml\                                  
                                                  Btl 90 mg/10 ml                                   

                                                                                                    

  Zoledronic acid (monohydrate)                   Btl 4 mg/5 ml\      IV\                           Prevention of SREs in cancer patients with bone metastases or MM (4 mg every 3--4 weeks).\
                                                  Btl 5 mg/100 ml     IV                            Treatment of hypercalcemia of malignancy\
                                                                                                    Treatment of osteoporosis in postmenopausal women, in men at increased risk of fracture, including those with a recent hip fracture from minor trauma (5 mg once per year)\
                                                                                                    Treatment of bone Paget\'s disease

                                                                                                    

  Denosumab                                       Btl 120 mg\         SC\                           Prevention of SREs in cancer patients with bone metastases (120 mg every 4 weeks)\
                                                  Btl 60 mg           SC                            Treatment of hypercalcemia of malignancy.\
                                                                                                    Osteoporosis (60 mg sc. every 6 months)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Main antiangiogenic drugs used (IV: intravenous; MM: multiple myeloma; PO: orally; SC: subcutaneous; Btl: bottle; Tab: tablet).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Pharmacologic active ingredient**   **Formulation**           **Route of administration**   **Indication and frequency**
  ------------------------------------- ------------------------- ----------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bevacizumab                           Btl 400 mg\               IV                            Metastatic breast cancer (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks); colorectal cancer (5 mg/kg or 10 mg/kg every 2 weeks); lung/ovarian cancer (7.5 mg/kg or 15 mg/kg every 3 weeks); renal cell cancer (10 mg/kg every 2 weeks); glioblastoma (10 mg/kg every 2 weeks)
                                        Btl 100 mg                                              

                                                                                                

  Sunitinib                             Tab 12.5 mg               PO                            Renal cell cancer, GISTs and neuroendocrine tumors (50 mg/day for 4 weeks)

                                                                                                

  Sorafenib                             Tab 200 mg                PO                            Renal cell cancer (800 mg/day)

                                                                                                

  Pazopanib                             Tab 200 mg\               PO                            Renal cell cancer (200--800 mg/day)
                                        Tab 400 mg                                              

                                                                                                

  Thalidomide                           Tab 50 mg                 PO                            Myeloma (400 mg/day for 6 weeks)

                                                                                                

  Lenalidomide                          Tab 5, 10, 15 and 25 mg   PO                            Myeloma (tailored doses)

                                                                                                

  Everolimus                            Tab 5 and 10 mg           PO                            Renal cell cancer, breast cancer (10 mg every day)

                                                                                                

  Temsirolimus                          Btl 30 mg                 IV                            Renal cell cancer (25 mg every week)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Drug-related risk factor of osteonecrosis of the jaw in the cancer population according to Campisi et al. 2011 \[[@B11]\].

  **Risk Factor**                        **Strenght**
  -------------------------------------- --------------
  Zoledronate vs Other Bisphosphonate    +++
                                         
  Intravenouse vs Oral Bisphosponate     ++
                                         
  Bisphosphonate cumulative dose         +++
                                         
  Bisphosphonate duration of treatment   +++
                                         
  Anti-angiogenic drugs                  ++
                                         
  Denosumab                              ++
                                         
  Chemotherapy                           -/+
                                         
  Thalilomide                            +/-

###### 

MRONJ staging according the AAOMS \[[@B7]\].

  **Stage**          **MRONJ clinical findings**
  ------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  At risk category   No apparent necrotic bone in patients who have been treated with either oral or IV bisphosphonates
                     
  Stage 0            No clinical evidence of necrotic bone, but non-specific clinical findings, radiographic changes and symptoms
                     
  Stage I            Exposed and necrotic bone, or fistulae that probes to bone, in patients who are asymptomatic and have no evidence of infection
                     
  Stage II           Exposed and necrotic bone, or fistulae that probes to bone, associated with infection as evidenced by pain and erythema in the region of the exposed bone with or without purulent drainage
                     
  Stage III          Exposed and necrotic bone or a fistula that probes to bone in patients with pain, infection, and one or more of the following: exposed and necrotic bone extending beyond the region of alveolar bone, (i.e., inferior border and ramus in the mandible, maxillary sinus and zygoma in the maxilla) resulting in pathologic fracture, extra-oral fistula, oral antral/oral nasal communication, or osteolysis extending to the inferior border of the mandible of sinus floor

###### 

Systematic review currently published and their limitations.

  **Systematic Review**                 **Limitation**
  ------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sacco et al. (2011) \[[@B53]\]        English literature limited search; Single Electronic database search.
                                        
  Vercruysse et al. (2014) \[[@B49]\]   Search Limited to BRONJ and or bisphosphonate related necrosis; No mentioning to language limitation; Review based on a single reviewer selection of articles
                                        
  Neto et al. (2016) \[[@B50]\]         Single Electronic database search; Search Limited to BRONJ and or bisphosphonate related necrosis; No mentioning to language limitation; No mentioning reviewer involved in the search strategy.

###### 

Study selected with total number of patient treated.

  **Study**                             **Type of study**   **Patients number**
  ------------------------------------- ------------------- ---------------------
  Engroff and Kim (2007) \[[@B38]\]     Case series         2
                                                            
  Ferrari et al. (2008) \[[@B39]\]      Case Report         1
                                                            
  Mücke et al. (2009) \[[@B36]\]        Case series         2
                                                            
  Nocini et al. (2009) \[[@B40]\]       Case series         7
                                                            
  Seth et al. (2010) \[[@B41]\]         Case series         11
                                                            
  Bedogni et al. (2011) \[[@B42]\]      Case series         3
                                                            
  Pautke et al. (2011) \[[@B43]\]       Case report         1
                                                            
  Bittner et al. (2012) \[[@B44]\]      Case report         1
                                                            
  Ghazali et al. (2013) \[[@B45]\]      Case report         1
                                                            
  Hanasono et al. (2013) \[[@B46]\]     Case series         11
                                                            
  Horta et al. (2014) \[[@B47]\]        Case series         1
                                                            
  Spinelli et al. (2014) \[[@B48]\]     Case series         8
                                                            
  Vercruysse et al. (2014) \[[@B49]\]   Case series         3
                                                            
  Kim et al. (2015) \[[@B51]\]          Case series         4
                                                            
  Mücke et al. (2016) \[[@B35]\]        Case series         14
                                                            
  Neto et al. (2016) \[[@B50]\]         Case report         1
                                                            
  Sotsuka et al. (2016) \[[@B52]\]      Case report         1
                                                            
  Caldroney et al. (2017) \[[@B37]\]    Case Series         11

###### 

Preoperative pharmacological analysis: type of drugs, indication for drug therapy, and time of drug exposure. ZOL: zoledronate; ALD: alendronate; PMT: pamidronate; COL: clodronate; DZM: denosumab; IBA: ibandronate; ETI: etidronate; mth: months; RSD: risedronate; NR: not reported.

  --------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                             **Type of drug**           **Indication for drug therapy**                 **time of drug exposure**
  ------------------------------------- -------------------------- ----------------------------------------------- ---------------------------------
  Engroff and Kim (2007) \[[@B38]\]     PMT (x 1 case)\            Brest Cancer (x 2 cases)                        NR
                                        ZOL (x 1 case)                                                             

                                                                                                                   

  Ferrari et al. (2008) \[[@B39]\]      PMT + ZOL                  Multiple Myeloma                                21 mth (PMT)\
                                                                                                                   3 mth (ZOL) discontinue therapy

                                                                                                                   

  Mücke et al. (2009) \[[@B36]\]        ZOL (x 2 cases)            Brest cancer (x 1 case);\                       50mth (ZOL)\
                                                                   Multiple Myeloma (x 1 case)                     36 mth (ZOL)

                                                                                                                   

  Nocini et al. (2009) \[[@B40]\]       PMT and ZOL (x 5 cases)\   Brest Cancer (x 5 cases);\                      NR
                                        ZOL (x 2 cases)            Prostate Cancer (x 1 case);\                    
                                                                   Myeloid leukaemia and Osteoporosis (x 1 case)   

                                                                                                                   

  Seth et al. (2010) \[[@B41]\]         ZOL (x 6 cases)\           Brest Cancer (x 5 cases);\                      NR
                                        ALD (x 2 cases)\           Prostate Cancer (x 2 cases);\                   
                                        IBA (x 2 cases)\           Multiple Myeloma (x 2 cases);\                  
                                        ETI (x 1 case)             Osteoporosis (x 2 cases)                        

                                                                                                                   

  Bedogni et al. (2011) \[[@B42]\]      NR                         NR                                              NR

                                                                                                                   

  Pautke et al. (2011) \[[@B43]\]       ZOL                        Prostate Cancer                                 40 mth

                                                                                                                   

  Bittner et al. (2012) \[[@B44]\]      ZOL and PMT                Pain syndrome                                   12 mth (ZOL)\
                                                                                                                   3 mth (PMT)

                                                                                                                   

  Ghazali et al. (2013) \[[@B45]\]      ALD                        Osteoporosis                                    84 mth (ALD)

                                                                                                                   

  Hanasono et al. (2013) \[[@B46]\]     ZOL (x 9 cases)\           Multiple Myeloma (x 5 cases);\                  NR
                                        PMT (x 2 cases)            Breast Cancer (x 2 cases);\                     
                                                                   Prostate Cancer (x 2 cases);\                   
                                                                   Osteoporosis (x 2 cases)                        

                                                                                                                   

  Horta et al. (2014) \[[@B47]\]        ZOL                        Lung Cancer                                     36 mth (ZOL)

                                                                                                                   

  Spinelli et al. (2014) \[[@B48]\]     ZOL (x 3 cases)\           Multiple Myeloma (x 4 cases);\                  1 x 27 mth (ZOL)\
                                        PMT (x 3 cases)\           Brest Cancer (x 3 cases);\                      1 x 21 mth (ZOL)\
                                        ZOL and PMT (x 2 cases)    Prostate Cancer (x 1 case)                      1 x 35 mth (ZOL\
                                                                                                                   1 x 22 mth (PMT)\
                                                                                                                   1 x 30 mth (PMT)\
                                                                                                                   1 x 19 mth (PMT\
                                                                                                                   1 x 25 mth (ZOL and PMT)\
                                                                                                                   1 x 17 mth (ZOL and PMT)

                                                                                                                   

  Vercruysse et al. (2014) \[[@B49]\]   1 x ZOL\                   Multiple Myeloma (x 2 case);\                   1 x 22mth (ZOL)\
                                        1 x ZOL + PMT\             Brest Cancer (x 1 case)                         1x 12 mth (PMT) + 26 mth (ZOL)\
                                        1 x ZOL + CLO                                                              1x 96 mth (CLO) + 29mth (ZOL)

                                                                                                                   

  Kim et al. (2015) \[[@B51]\]          ALD (x 2)\                 Osteoporosis (x 3)\                             1 x 48 mth (ALD)\
                                        ALD + RSD + PMT (x 1)\     Multiple Myeloma (x 1)                          1 x 120 mth (ALD\
                                        ZOL + PMT (x 1)                                                            1 x 24 mth (ALD + RSD +PMT)\
                                                                                                                   1 x 30mth (ZOL +PMT)

                                                                                                                   

  Mücke et al. (2016) \[[@B35]\]        NR                         NR                                              NR

                                                                                                                   

  Neto et al. (2016) \[[@B50]\]         ZOL                        Lung Cancer                                     36 mth (ZOL)

                                                                                                                   

  Sotsuka et al (2016) \[[@B52]\]       ZOL                        Brest Cancer                                    59 mth (ZOL)

                                                                                                                   

  Caldroney et al. (2017) \[[@B37]\]    7 x ZOL\                   Brest Cancer (x 4 cases)\                       NR
                                        2 x ALD\                   Osteoporosi (x 3 cases)\                        
                                        1 x ZOL + DZM\             Multiple Myeloma (x 3 cases)\                   
                                        1 x PMT + DZM              Prostate Cancer (x 1 case)                      
  --------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Preoperative epidemiologic analysis (age, sex, predisposing factors, and site of the necrosis involved). M: male; F: female; NR: not reported.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                             **Type of study**   **Patients number**   **Age/Sex**                                                                               **Trigging cause**                                      **Site of the necrosis involved**
  ------------------------------------- ------------------- --------------------- ----------------------------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------
  Engroff and Kim (2007) \[[@B38]\]     Case series         2                     64 (F); 49 (F)                                                                            Dental extraction (x 2 cases)                           Mandible (x 2 cases)

                                                                                                                                                                                                                                    

  Ferrari et al. (2008) \[[@B39]\]      Case report         1                     66 (M)                                                                                    NR                                                      Mandible

                                                                                                                                                                                                                                    

  Mücke et al. (2009) \[[@B36]\]        Case series         2                     48 (F); 60 (F)                                                                            Dental Extraction (x 1 case); Spontaneous (x 1 case)    Mandible (x 2 cases)

                                                                                                                                                                                                                                    

  Nocini et al. (2009) \[[@B40]\]       Case series         7                     NR (six F); (one M)                                                                       Oral surgery (x 5 cases);\                              Mandible (x 7 cases)
                                                                                                                                                                            Infection (x 2 cases)                                   

                                                                                                                                                                                                                                    

  Seth et al. (2010) \[[@B41]\]         Case series         11                    68 (M); 56 (F); 50 (F); 72 (F); 48 (F); 71 (F); 67 (F); 60 (F); 51 (F); 72 (M); 60 (F)    NR                                                      Mandible (x 11 cases)

                                                                                                                                                                                                                                    

  Bedogni et al. (2011) \[[@B42]\]      Case series         3                     NR                                                                                        NR                                                      Mandible (x 2 cases); Maxilla (x 1 case)

                                                                                                                                                                                                                                    

  Pautke et al. (2011) \[[@B43]\]       Case report         1                     76 (M)                                                                                    Dental extraction                                       Mandible

                                                                                                                                                                                                                                    

  Bittner et al. (2012) \[[@B44]\]      Case report         1                     41 (F)                                                                                    Dental extraction                                       Mandible

                                                                                                                                                                                                                                    

  Ghazali et al. (2013) \[[@B45]\]      Case report         1                     82 (F)                                                                                    Dental extraction                                       Mandible

                                                                                                                                                                                                                                    

  Hanasono et al. (2013) \[[@B46]\]     Case series         11                    63 (F); 57 (M); 65 (M); 75 (F); 72 (M); 68 (M); 60 (F); 64 (F); 70 (F); 75 (F); 67 (F)    NR                                                      Mandible (x 11 cases)

                                                                                                                                                                                                                                    

  Horta et al. (2014) \[[@B47]\]        Case series         1                     54 M                                                                                      Spontaneous                                             Mandible

                                                                                                                                                                                                                                    

  Spinelli et al. (2014) \[[@B48]\]     Case series         8                     73 (M); 77 (F); 64 (F); 53 (F); 62 (M); 68 (F); 57 (M); 64 (F)                            Dental extraction (x 3 cases); Spontaneous x 5          Mandible (x 8 cases)

                                                                                                                                                                                                                                    

  Vercruysse et al. (2014) \[[@B49]\]   Case series         3                     54 (F); 70 (F); 64 (F)                                                                    Dental extraction (x 1 case); Spontaneous (x 2 cases)   Mandible (x 3 cases)

                                                                                                                                                                                                                                    

  Kim et al. (2015) \[[@B51]\]          Case series         4                     69 (F), 68 (F), 62 (F), 70 (M)                                                            NR                                                      Mandible (x 4)

                                                                                                                                                                                                                                    

  Mücke et al. (2016) \[[@B35]\]        Case series         14                    NR                                                                                        NR                                                      Mandible (x 14 cases)

                                                                                                                                                                                                                                    

  Neto et al. (2016) \[[@B50]\]         Case report         1                     58 (M)                                                                                    Spontaneous                                             Mandible

                                                                                                                                                                                                                                    

  Sotsuka et al. (2016) \[[@B52]\]      Case report         1                     50 (F)                                                                                    NR                                                      Maxilla

                                                                                                                                                                                                                                    

  Caldroney et al. (2017) \[[@B37]\]    Case series         11                    56 (F); 65 (F); 60 (F); 61 (F); 65 (F); 64 (F); 68 (M); 67 (M); 73 (M); 72 (F); 73 (M).   NR                                                      Mandible (x 11 cases)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Operative analysis: type of surgery, type of free flap, flap failure, immediate postoperative complications (FFF: fibula Free flap; ICFF: iliac crest free flap; SFF: scapula free flap).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                             **Type of surgery**          **Type of free flap**   **Flap failure**               **Immediate post-operative complications**
  ------------------------------------- ---------------------------- ----------------------- ------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Engroff and Kim (2007) \[[@B38]\]     2 x Segmental                2 x FFF                 0                              Small Neck hematoma in one patient

                                                                                                                            

  Ferrari et al. (2008) \[[@B39]\]      Sub-total                    1x FFF                  0                              0

                                                                                                                            

  Mücke et al. (2009) \[[@B36]\]        2 x Segmental                1 x FFF; 1x ICFF        0                              0

                                                                                                                            

  Nocini et al. (2009) \[[@B40]\]       7 x Subtotal                 7 x FFF                 0                              Rupture of mini-plate in one patient

                                                                                                                            

  Seth et al. (2010) \[[@B41]\]         NR                           11 x FFF                0                              Prolonged infection in one patient; Fistula and infection in three patients.

                                                                                                                            

  Bedogni et al. (2011) \[[@B42]\]      NR                           3 x FFF                 1 (a year later)               0

                                                                                                                            

  Pautke et al. (2011) \[[@B43]\]       Segmental                    1 x ICFF                0                              Fistula resolved with removal of plate

                                                                                                                            

  Bittner et al. (2012) \[[@B44]\]      Segmental                    1 x SFF                 0                              0

                                                                                                                            

  Ghazali et al. (2013) \[[@B45]\]      Segmental                    1 x FFF                 0                              Sinus bradycardia

                                                                                                                            

  Hanasono et al. (2013) \[[@B46]\]     6 x subtotal\                11 x FFF                1                              Hematoma in one patient; Pneumonia in one patient; Deep vein thrombosis in one patient; Small bowel obstruction in one patient. All complications occurred in FFF
                                        5 x segmental                                                                       

                                                                                                                            

  Horta et al. (2014) \[[@B47]\]        1 x segmental                1 x FFF                 0                              0

                                                                                                                            

  Spinelli et al. (2014) \[[@B48]\]     8 x subtotal                 8 x FFF                 0                              0

                                                                                                                            

  Vercruysse et al. (2014) \[[@B49]\]   2 x Partial; 1 x Segmental   3 x ICFF                1 (segmental- 16 days later)   1 (failure)

                                                                                                                            

  Kim et al. (2015) \[[@B51]\]          NR                           4 x FFF                 0                              0

                                                                                                                            

  Mücke et al. (2016) \[[@B35]\]        NR                           9 x FFF\                NR                             NR
                                                                     5 x ICFF                                               

                                                                                                                            

  Neto et al. (2016) \[[@B50]\]         1 x segmental                1 x FFF                 0                              0

                                                                                                                            

  Sotsuka et al. (2016) \[[@B52]\]      NR                           1 x FFF                 0                              0

                                                                                                                            

  Caldroney et al. (2017) \[[@B37]\]    6 x segmental\               4 x SFF\                0                              Two cases with wound infection and dehiscence and one case the plate was removed. (3 different patients). One FFF and two SFF
                                        5 x sub total                7 x FFF                                                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Complications during follow-up time.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                             **Follow-up time**    **Complications during follow-up (included plate removal)**   **MRONJ recurrence**               **Site of recurrence**
  ------------------------------------- --------------------- ------------------------------------------------------------- ---------------------------------- -------------------------
  Engroff and Kim (2007) \[[@B38]\]     2x12 months           0                                                             Recurrence in one patient          Contralateral

                                                                                                                                                               

  Ferrari et al. (2008) \[[@B39]\]      1 x 12 months         Plate removal                                                 0                                  0

                                                                                                                                                               

  Mücke et al. (2009) \[[@B36]\]        2x 12 months          0                                                             0                                  0

                                                                                                                                                               

  Nocini et al. (2009) \[[@B40]\]       1x 6 months\          0                                                             Recurrence in one patient          Margin of the resection
                                        1 x 16 months\                                                                                                         
                                        1 x 23 months\                                                                                                         
                                        1 x 24 months\                                                                                                         
                                        1 x 19 months\                                                                                                         
                                        1 x 33 months\                                                                                                         
                                        1 x 34 months                                                                                                          

                                                                                                                                                               

  Seth et al. (2010) \[[@B41]\]         1 x 10.0 months\      0                                                             0                                  0
                                        1x 0.5 months\                                                                                                         
                                        1x 30.8 months\                                                                                                        
                                        1x 21.4 months\                                                                                                        
                                        1x 17.8 months\                                                                                                        
                                        1x 23.7 months\                                                                                                        
                                        1x 10.6 months\                                                                                                        
                                        1 x 14.2 months\                                                                                                       
                                        1x 13.9 months\                                                                                                        
                                        1x 12.2 months\                                                                                                        
                                        1x 6.1 months                                                                                                          

                                                                                                                                                               

  Bedogni et al. (2011) \[[@B42]\]      NR                    failure of the FFF 1 year later                               0                                  0

                                                                                                                                                               

  Pautke et al. (2011) \[[@B43]\]       NR                    plate removal                                                 Recurrence in one patient          On the free flap

                                                                                                                                                               

  Bittner et al. (2012) \[[@B44]\]      NR                    0                                                             0                                  0

                                                                                                                                                               

  Ghazali et al. (2013) \[[@B45]\]      24 months             0                                                             0                                  0

                                                                                                                                                               

  Hanasono et al. (2013) \[[@B46]\]     1 x 13.3 months\      0                                                             0                                  0
                                        1x 20.1 months\                                                                                                        
                                        1x 77.0 months\                                                                                                        
                                        1x 23.8 months\                                                                                                        
                                        1x 11.4 months\                                                                                                        
                                        1 x 9.1 months\                                                                                                        
                                        1x 9.1 months\                                                                                                         
                                        1x 9.1 months\                                                                                                         
                                        1x 8.1 months\                                                                                                         
                                        2 x 3.0 months                                                                                                         

                                                                                                                                                               

  Horta et al. (2014) \[[@B47]\]        1 x 12 months         0                                                             0                                  0

                                                                                                                                                               

  Spinelli et al. (2014) \[[@B48]\]     1x 21.7 months\       0                                                             0                                  0
                                        1x 25.1 months\                                                                                                        
                                        1x 28.4 months\                                                                                                        
                                        1x 32.2 months\                                                                                                        
                                        1x 37 months\                                                                                                          
                                        1x 28.4 months\                                                                                                        
                                        1x 25.1 months\                                                                                                        
                                        1x 32.9 months                                                                                                         

                                                                                                                                                               

  Vercruysse et al. (2014) \[[@B49]\]   1x 36 months\         Plate removal in one patient                                  Recurrence in one patient          Contralateral
                                        1x 65 months\                                                                                                          
                                        1x 76 months                                                                                                           

                                                                                                                                                               

  Kim et al. (2015) \[[@B51]\]          1 x 99 months\        Fracture of plate in one patient                              0                                  0
                                        1 x 18 months\                                                                                                         
                                        1 x 12 months\                                                                                                         
                                        1 x 7 months                                                                                                           

                                                                                                                                                               

  Mücke et al. (2016) \[[@B35]\]        34.25 ± 33.3 months   \-                                                            Recurrence in one of the patient   Margin of the flap

                                                                                                                                                               

  Neto et al. (2016) \[[@B50]\]         1 x 48 months         0                                                             0                                  0

                                                                                                                                                               

  Sotsuka et al. (2016) \[[@B52]\]      NR                    0                                                             0                                  0

                                                                                                                                                               

  Caldroney et al. (2017) \[[@B37]\]    3 x 6 months\         Plate removal in one patient                                  0                                  0
                                        2 x 44 months\                                                                                                         
                                        1 x 69 months\                                                                                                         
                                        1 x 36 months\                                                                                                         
                                        1 x 28 months\                                                                                                         
                                        1 x 10 months\                                                                                                         
                                        1 x 17 months\                                                                                                         
                                        1 x 11 months                                                                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[^1]: Academic Editor: Noam Yarom
